AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35288397 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin and placebo
Number of subjects: 46
Study 33547689 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral readouts with long waveform (45 ms)
Number of subjects: 0
Study 33547689 — intervention group
Group type: COMPARATOR
Intervention: Spiral readouts with short waveform (26 ms)
Number of subjects: 0
Study 33547689 — intervention group
Group type: EXPERIMENTAL
Intervention: f0-map correction
Number of subjects: 0
Study 32423126 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 45
Study 32423126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Power Training and Traditional Resistance Training (PTRT)
Number of subjects: 45
Study 32423126 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study 35597230 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anthocyanin intake (>10 mg/d)
Number of subjects: 40
Study 35597230 — intervention group
Group type: COMPARATOR
Intervention: Lower anthocyanin intake (<10 mg/d)
Number of subjects: 40
Study 32895971 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral erythromycin estolate (250 mg) + Intravenous metoclopramide (10 mg every 6-8 hours)
Number of subjects: 35
Study 32895971 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide (10 mg every 6-8 hours) + Placebo (every 6 hours for 7 days)
Number of subjects: 35
Study 32895971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 34275664 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACS-I
Number of subjects: 167
Study 34275664 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACS-II
Number of subjects: 167
Study 34275664 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 167
Study 32032916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.2 mg.kg‐1
Number of subjects: 61
Study 32032916 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1 mg.kg‐1
Number of subjects: 61
Study 36241872 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (5-7.5 mg)
Number of subjects: 20
Study 36241872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34010787 — intervention group
Group type: EXPERIMENTAL
Intervention: ALLR3 trial
Number of subjects: 393
Study 34010787 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with good MRD response
Number of subjects: 393
Study 34010787 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-SCT for BCP-ALL
Number of subjects: 393
Study 34010787 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-SCT for T-ALL
Number of subjects: 393
Study 32808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 336997
Study 32808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 336997
Study 32808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 336997
Study 32808034 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI, Alcohol intake, Smoking
Number of subjects: 336997
Study 32808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression, Asthma, Migraines
Number of subjects: 336997
Study 36328383 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case (BC/WC) communication tool training for nephrologists
Number of subjects: 320
Study 36328383 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study 35952316 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscore-High tumors in low-risk group
Number of subjects: 600
Study 35952316 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscore-Low tumors in low-risk group
Number of subjects: 600
Study 35952316 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscore-High tumors in high-risk group
Number of subjects: 600
Study 35952316 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscore-Low tumors in high-risk group
Number of subjects: 600
Study 35952316 — intervention group
Group type: COMPARATOR
Intervention: Low-risk/Immunoscore-Low tumors
Number of subjects: 600
Study 33030349 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD)
Number of subjects: 67
Study 33030349 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 67
Study 33030349 — intervention group
Group type: COMPARATOR
Intervention: Control (Routine breast care)
Number of subjects: 67
Study 32658890 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline skin autofluorescence (SAF)
Number of subjects: 1707
Study 32658890 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in SAF over 1 year
Number of subjects: 1707
Study 36055959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 260
Study 36055959 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 260
Study 36299233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungitell® beta-D-glucan (BDG) assay
Number of subjects: 51
Study 34625409 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote methods of genetic education about the risks of inherited PDAC and strategies for surveillance.
Number of subjects: 98
Study 32044712 — intervention group
Group type: EXPERIMENTAL
Intervention: veridical rt‐fMRI‐nf
Number of subjects: 32
Study 32044712 — intervention group
Group type: COMPARATOR
Intervention: sham (yoked) feedback
Number of subjects: 32
Study 35373583 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 229
Study 35373583 — intervention group
Group type: COMPARATOR
Intervention: Dual Antiplatelet Therapy (aspirin plus clopidogrel)
Number of subjects: 229
Study 34768338 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen titration
Number of subjects: 33
Study 34768338 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose oxygen treatment
Number of subjects: 33
Study 32951712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum myofascial therapy device (VT)
Number of subjects: 38
Study 32951712 — intervention group
Group type: COMPARATOR
Intervention: Comparison physical therapy program (PTP)
Number of subjects: 38
Study 33189285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate (6 mM)
Number of subjects: 0
Study 33189285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (100 nM)
Number of subjects: 0
Study 33189285 — intervention group
Group type: EXPERIMENTAL
Intervention: eIF4E siRNA
Number of subjects: 0
Study 33189285 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 mM acetate)
Number of subjects: 0
Study 34872625 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (CBT) for ED-PTSD
Number of subjects: 42
Study 34872625 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT for ED
Number of subjects: 42
Study 36461632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 123
Study 36461632 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study 34597010 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic mastectomy
Number of subjects: 80
Study 34597010 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 80
Study 34140460 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet CBT (Pancreatitis Pain Course)
Number of subjects: 30
Study 34140460 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 32769842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B lenses packaged in and cared for with EOBO-containing solutions (CLEAR CARE PLUS with HydraGlyde or OPTI-FREE PUREMOIST)
Number of subjects: 143
Study 32769842 — intervention group
Group type: COMPARATOR
Intervention: Senofilcon C lenses with non-EOBO MPS
Number of subjects: 143
Study 32769842 — intervention group
Group type: COMPARATOR
Intervention: Senofilcon A lenses with non-EOBO MPS
Number of subjects: 143
Study 32769842 — intervention group
Group type: COMPARATOR
Intervention: Comfilcon A lenses with non-EOBO MPS
Number of subjects: 143
Study 32769842 — intervention group
Group type: COMPARATOR
Intervention: Samfilcon A lenses with non-EOBO MPS
Number of subjects: 143
Study 36397223 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-element music therapy, 30 min each session, once every two days, 3 treatments a week for 4 weeks.
Number of subjects: 60
Study 36397223 — intervention group
Group type: COMPARATOR
Intervention: Conventional health education (control group).
Number of subjects: 60
Study 36397223 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-element music therapy.
Number of subjects: 60
Study 33857180 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth exercises
Number of subjects: 28
Study 33857180 — intervention group
Group type: COMPARATOR
Intervention: Core stabilization exercises
Number of subjects: 28
Study 36129521 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 13, standard dose every 10 days)
Number of subjects: 24
Study 36129521 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB (n = 11, thrice weekly)
Number of subjects: 24
Study 33423540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 94
Study 33423540 — intervention group
Group type: COMPARATOR
Intervention: Warfarin plus aspirin
Number of subjects: 94
Study 32383615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (5mg/kg slow intravenous injection)
Number of subjects: 56
Study 32383615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL/kg of intravenous 10% solution of dextrose saline)
Number of subjects: 56
Study 32298600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hala system
Number of subjects: 160
Study 32298600 — intervention group
Group type: COMPARATOR
Intervention: Research survey system
Number of subjects: 160
Study 34534071 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week adjunctive bright light therapy with a gradual advance protocol
Number of subjects: 91
Study 32001805 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic ancestry analysis using a panel of 192 polymorphic markers
Number of subjects: 1358
Study 32001805 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased African genetic ancestry
Number of subjects: 1358
Study 32001805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 1358
Study 35726738 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorado Protocol (aspirin, steroid, and antibiotic)
Number of subjects: 289
Study 35726738 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of a trial
Number of subjects: 289
Study 35726738 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorado Protocol
Number of subjects: 289
Study 33436380 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention targeting managers with a 3-hour seminar addressing needs and options for adjustment of work in pregnancy.
Number of subjects: 915
Study 33436380 — intervention group
Group type: COMPARATOR
Intervention: Control group with practice as usual.
Number of subjects: 915
Study 32977216 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (10-20 minutes per session)
Number of subjects: 2494
Study 32977216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint or specific body reflex area massage
Number of subjects: 2494
Study 32977216 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage delivered by professionals and non-professionals
Number of subjects: 2494
Study 32977216 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 2494
Study 35791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 250 mg Q4W
Number of subjects: 530
Study 35791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 250 mg Q4W/125 mg Q8W
Number of subjects: 530
Study 35791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 250 mg Q4W/250 mg Q8W
Number of subjects: 530
Study 35791755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 33080034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (10,000 lux)
Number of subjects: 35
Study 33080034 — intervention group
Group type: COMPARATOR
Intervention: Red dim light (100 lux)
Number of subjects: 35
Study 33080034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 35
Study 35063011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization (DNS) exercise
Number of subjects: 64
Study 35063011 — intervention group
Group type: COMPARATOR
Intervention: Core stability (CS) exercises
Number of subjects: 64
Study 34798030 — intervention group
Group type: COMPARATOR
Intervention: Handwashing stations only
Number of subjects: 75
Study 34798030 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of normative social behaviour (TNSB) intervention including provision of handwashing stations
Number of subjects: 75
Study 34798030 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study 32585673 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery (ROB)
Number of subjects: 40
Study 32585673 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 40
Study 32585673 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery (OPEN)
Number of subjects: 40
Study 32585673 — intervention group
Group type: COMPARATOR
Intervention: Control group (motor training without surgical instruments)
Number of subjects: 40
Study 34932153 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 50
Study 32273219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Care Without a Battle (MCWB) intervention
Number of subjects: 434
Study 32273219 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-MCWB homes)
Number of subjects: 434
Study 35737952 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 100
Study 35737952 — intervention group
Group type: COMPARATOR
Intervention: Swaddling
Number of subjects: 100
Study 34088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH) - 6 practices, consisting of a health survey followed by collaborative action planning
Number of subjects: 725
Study 34088821 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Engagement CTH (EE-CTH) - 6 practices, including additional training in relationship building promoting patient engagement
Number of subjects: 725
Study 34088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health literacy
Number of subjects: 725
Study 34088821 — intervention group
Group type: EXPERIMENTAL
Intervention: No social risks
Number of subjects: 725
Study 34088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quality action plans
Number of subjects: 725
Study 35144067 — intervention group
Group type: EXPERIMENTAL
Intervention: Labour roadmap with birth balls
Number of subjects: 0
Study 35144067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 35534825 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg
Number of subjects: 50
Study 35534825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 35080187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 2.5 mg/kg d1, d8 (group A)
Number of subjects: 20
Study 35080187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg d1, d8 (group B)
Number of subjects: 20
Study 35080187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg d1, d8 (group C)
Number of subjects: 20
Study 34530885 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation procedure (arm B)
Number of subjects: 100
Study 34530885 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure (arm A)
Number of subjects: 100
Study 35701011 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 150 mg
Number of subjects: 0
Study 35701011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 33255704 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Capital Intervention (PCI) using a daily online self-learning approach
Number of subjects: 104
Study 33255704 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study 616886769 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine-based nursing care
Number of subjects: 60
Study 616886769 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 60
Study 35801287 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodex training
Number of subjects: 89
Study 35801287 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical balance training
Number of subjects: 89
Study 35801287 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 32901526 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal vitamin C
Number of subjects: 0
Study 32901526 — intervention group
Group type: COMPARATOR
Intervention: Non-liposomal vitamin C
Number of subjects: 0
Study 32056053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 1193
Study 32056053 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 1193
Study 33040208 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematically aligned total knee arthroplasty (KA TKA) with a posterior-stabilizing (PS) prosthesis
Number of subjects: 14
Study 33040208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) total knee arthroplasty (TKA)
Number of subjects: 14
Study 33040208 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilizing (PS) total knee arthroplasty (TKA)
Number of subjects: 14
Study 33040208 — intervention group
Group type: COMPARATOR
Intervention: Mechanically aligned total knee arthroplasty (MA TKA) with a PS prosthesis
Number of subjects: 14
Study 32329033 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT intervention
Number of subjects: 352
Study 35433385 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 80
Study 35433385 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 80
Study 32410636 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) technique
Number of subjects: 160
Study 32410636 — intervention group
Group type: COMPARATOR
Intervention: Standard Free-Hand (FH) technique
Number of subjects: 160
Study 35613184 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 4274
Study 35613184 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4274
Study 32706502 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 30
Study 32706502 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 32706502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 35759004 — intervention group
Group type: EXPERIMENTAL
Intervention: State-funded pre-kindergarten (pre-K) program
Number of subjects: 2990
Study 32696031 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic moxifloxacin (MXF) with subgingival debridement (SD)
Number of subjects: 36
Study 32696031 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus metronidazole (AM+MT) combined with SD
Number of subjects: 36
Study 32696031 — intervention group
Group type: COMPARATOR
Intervention: Subgingival debridement (SD) alone
Number of subjects: 36
Study 32581088 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (4×375 mg/m2) and glucocorticoids (higher or lower dose regimen)
Number of subjects: 188
Study 32581088 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and glucocorticoids
Number of subjects: 188
Study 36328390 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Number of subjects: 0
Study 36328390 — intervention group
Group type: COMPARATOR
Intervention: Treadmill gait training alone
Number of subjects: 0
Study 32686996 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI-Programme
Number of subjects: 36
Study 32686996 — intervention group
Group type: COMPARATOR
Intervention: FIFA11+
Number of subjects: 36
Study 34211330 — intervention group
Group type: EXPERIMENTAL
Intervention: early‐pubertal training
Number of subjects: 178
Study 34211330 — intervention group
Group type: COMPARATOR
Intervention: early‐pubertal control
Number of subjects: 178
Study 34211330 — intervention group
Group type: EXPERIMENTAL
Intervention: post‐pubertal training
Number of subjects: 178
Study 34211330 — intervention group
Group type: COMPARATOR
Intervention: post‐pubertal control
Number of subjects: 178
Study 35443845 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat agency
Number of subjects: 0
Study 35443845 — intervention group
Group type: COMPARATOR
Intervention: Human agency
Number of subjects: 0
Study 35443845 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat agency for threats not ascribed to humans
Number of subjects: 0
Study 35443845 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat agency for threats ascribed to humans
Number of subjects: 0
Study 33951241 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked and very briefly presented food images
Number of subjects: 60
Study 33951241 — intervention group
Group type: COMPARATOR
Intervention: Clearly visible food images
Number of subjects: 60
Study 33951241 — intervention group
Group type: COMPARATOR
Intervention: Masked non-food images (household items)
Number of subjects: 60
Study 32422870 — intervention group
Group type: EXPERIMENTAL
Intervention: Seapolynol isolated from Ecklonia cava
Number of subjects: 0
Study 32422870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36183042 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon 20-mg triamcinolone injection (TA group)
Number of subjects: 140
Study 36183042 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone eye drops (Dexa group)
Number of subjects: 140
Study 32701208 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative afferent pupillary defect (RAPD) assessment at diagnosis or one month
Number of subjects: 101